Register here

Fill out your contact information and listing information for the Site Locator below. You will
receive confirmation via email to the address listed in the contact information section.

Fields marked with an asterisk (*) are required.

Step 1 of 3: Contact information

This information will be used to contact you about your listing and will not be listed in the Site Locator.

What is your role at your practice?

Step 2 of 3: Listing information

This information will appear when a user searches
for a practice near them using the Site Locator.

OFFICE SPECIALTY* (choose all that apply)

Your registration will be complete after you read and acknowledge the Release below and click Submit.

Step 3 of 3: Release to Publish Practice Information on UCB CIMZIA Website

The Practice understands that UCB, Inc., its affiliates and/or designees (“UCB”) would like to use contact information for the Practice on UCB’s In-Office Injection website, at (“CIMZIA IOI Website”). Specifically, UCB will publish the following information for the Practice: (i) Practice name; (ii) Practice specialty; (iii) Practice address; (iv) Practice telephone number; and (v) Practice website (together, the “Practice Information”). The Practice understands that UCB would like to share the Practice Information as part of an online database of providers that offer CIMZIA In-Office Injection to patients with a prescription from a physician to allow these patients to search for nearby CIMZIA providers and contact information ("Site Locator").

By opting-in to this Release, I am authorizing UCB and/or its affiliates to publish the Practice Information on The Practice hereby grants permission to UCB to publish the Practice Information on the CIMZIA IOI Website and/or Site Locator for the purposes outlined in this Release. 

Please note that to be included in the CIMZIA IOI Website and/or the Site Locator, the Practice must have a valid state license to stock and administer CIMZIA In-Office Injections.  UCB will verify your submission and inform you when the Site Locator is ready to launch.

The Practice understands and agrees that:

(1) The Practice has the right to refuse to sign this Release and, in doing so, UCB will not publish the Practice Information on UCB’s IOI Website and/or the Site Locator;
(2) The Practice has the right to receive and/or request a copy of this Release at any time;
(3) The Practice may revoke the authorization given in this Release at any time by providing written notice of the same to UCB, and upon receipt of this 
revocation notice, UCB will delete the Practice Information from the CIMZIA IOI Website and/or Site Locator; 
(4) The Practice will inform CIMZIA of any changes to the published Practice Information and/or if the Practice ceases the administration of CIMZIA in-office 
injections to prescribed patients;
(5) The Practice is responsible for any errors in the published Practice Information that are caused by the Practice; 
(6) UCB may contact the Practice for the purpose of communicating any updates, changes, or any other news regarding the CIMZIA IOI Website and/or the Site Locator; 
(7) UCB will exercise its discretion as to whether and when to provide listings in the CIMZIA IOI Website and/or the Site Locator for particular geographic areas, and may exercise its discretion not to provide listings for certain geographic areas; 
(8) The inclusion of the Practice in the CIMZIA IOI Website and/or the Site Locator is not an endorsement, referral, or recommendation from UCB of the Practice; and
(9) Nothing has created or vested in the Practice any ownership, copyright, or other rights in the CIMZIA IOI Website and/or the Site Locator by virtue of this Release.

The Practice further releases UCB and its respective agents from any and all liability in connection with the publication of the Practice Information on the CIMZIA IOI Website and/or the Site Locator in accordance with this Release. The Practice will neither seek nor bring any proceedings against any such parties for any claim or cause of action based upon or relating to the publication of the Practice Information pursuant to this Release.

At any time, you may unsubscribe from the mailing list as well as review the Privacy Policy.

View full Terms of Use.

Inclusion in the In-Office Injection Site Locator is subject to approval. It is anticipated that the In-Office Injection Site Locator will include the practice name, specialty, address, telephone number, and website if provided. The inclusion of any location in the In-Office Injection Site Locator is not an endorsement, referral, or recommendation from UCB of that practice. Return to the top to register your practice location.



Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.


CIMZIA is indicated for:

  • Reducing signs and symptoms of Crohn’s disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
  • Treatment of adults with moderately to severely active rheumatoid arthritis (RA)
  • Treatment of adult patients with active psoriatic arthritis (PsA)
  • Treatment of adult patients with active ankylosing spondylitis (AS)
  • Treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy
  • Treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation



CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.


Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use.
  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

  • Do not start CIMZIA during an active infection, including localized infections.
  • Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
  • If an infection develops, monitor carefully and initiate appropriate therapy.


Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

  • Consider the risks and benefits of CIMZIA treatment prior to initiating or continuing therapy in a patient with known malignancy.
  • In clinical trials, more cases of malignancies were observed among CIMZIA-treated patients compared to control patients.
  • In CIMZIA clinical trials, there was an approximately 2-fold higher rate of lymphoma than expected in the general U.S. population. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk of lymphoma than the general population.
  • Malignancies, some fatal, have been reported among children, adolescents, and young adults being treated with TNF blockers. Approximately half of the cases were lymphoma, while the rest were other types of malignancies, including rare types associated with immunosuppression and malignancies not usually seen in this patient population.
  • Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including CIMZIA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis, and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treating with CIMZIA in these patient types.
  • Cases of acute and chronic leukemia were reported with TNF blocker use.


  • Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers. Exercise caution and monitor carefully.


  • Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness, and urticaria have been reported following CIMZIA administration. If a serious allergic reaction occurs, stop CIMZIA and institute appropriate therapy. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a derivative of natural rubber latex which may cause an allergic reaction in individuals sensitive to latex.


  • Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
  • Test patients for HBV infection before initiating treatment with CIMZIA.
  • Exercise caution in patients who are carriers of HBV and monitor them before and during CIMZIA treatment.
  • Discontinue CIMZIA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatment.


  • TNF blockers, including CIMZIA, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, seizure disorder, optic neuritis, peripheral neuropathy, and Guillain-Barré syndrome.


  • Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with CIMZIA.
  • Consider stopping CIMZIA if significant hematologic abnormalities occur.


  • Do not use CIMZIA in combination with other biological DMARDS.


  • Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.


  • Patients on CIMZIA should not receive live or live-attenuated vaccines.


  • The most common adverse reactions in CIMZIA clinical trials (≥8%) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).

Please see full Prescribing Information.